Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug

fiercebiotechSeptember 06, 2018

Tag: NEA , AstraZeneca , Brilinta

PharmaSources Customer Service